The 33 drugs that are developed in new drug development, second only to the United States and Japan, are only available locally!

In the past 10 years, Japan's exclusive market for new drugs
Japanese new drugs with small molecular drugs as the main driving force
Japanese pharmaceutical companies, including Ono, Concord fermentation Kirin, Sino-foreign pharmaceutical companies have successfully developed a number of innovative biological drugs, and independent or cooperation in Japan and Europe and the United States listedThe japanese drug market, including antibodies, accounts for only about one-third of the world's biological drugs, about 70% of approved antibody drugs also come from non-Japanese pharmaceutical companies, and only in Japan to market new drugs of small and molecular drugs accounted for 90%Japan because of the incentive biotechnology research commercialization policy is not perfect, the main new drug research and development enterprises are mainly internal development, biological new drug research and development speed compared with small innovative pharmaceutical companies in Europe and the United States is slowerThe proportion of native biologic drugs in Japan (right) is lower than the proportion of global biologic drugs (left)the exclusive market of 3 anti-tumor drugs in Europe and the United States have encountered Waterlooin the past 10 years, Japan approved the highest proportion of new drugs anti-tumor drugs, Japan's exclusive listing of anti-tumor drugs only 3target FLT3-ITD rare mutation asmall asmall molecule drug Quizartinib is the only anti-tumor drug available in Japan this year, the FLT3-ITD selection inhibition activity is high and had high hopes, in the EMA to obtain orphan drugs and accelerated review qualification, in the FDA to obtain a breakthrough The rapyand and quick-review channel eligibility, but not approved because regulators in both regions considered the trial data inherently biased, leaving the First Third in the development of new drugs for AML with FLT3 mutations behind Novartis's Midostaurin and Gilteritinib of AstellasClinical trials of Quizartinib on Clinicaltrial seine in Europe, The United States and China are still ongoingForodesine was approved in 2017 for use in T-cell lymphoma pediatric patients, which regulates the phospholytic reaction of bird nucleic acid by targeting thorium nucleic acid phosphatase (PNP), resulting in intracellular nucleic acid metabolism imbalance, which induces T-cell death, there is no significant change in the number of B cells, the evidence at the gene level only supports the application of PNP as a therapeutic target, but does not fully reflect the safety information of the targetThe decline in the number of T-cells directly leads to an increased risk of infection, and some patients also have secondary tumors caused by EBV virus infection, greatly limiting the clinical application value of the drugAs a result, follow-up development was halted in both the United States and JapanMiriplatin hydrate mita is a fat-soluble platinum class, dissolved in a third-generation platinum anti-cancer drug that is used in special lysing fluid iodized oil, within the liver artery, for traditional hepatic arterial embolism chemotherapySince Europe and the United States have been commonly used cisplatin and dojoo than star, rice platinum in Europe and the United States does not have much development and replacement value, so it is currently only used for Japanese patientsconditional approval of Japan's first exclusive gene therapyfollowing Novartis' Kymriah, this year Japan through conditional approval to market the second, Japan's self-developed gene therapy, Collategene, hepatocellular growth factor cDNA and transfer to human cells to produce new blood vessels, used to treat severe limb ischemia, about 150,000 diabetics in Japan every year limb ischemia risk of amputation The therapy needs to be fully approved for post-market evaluation within 5 years and is currently being awarded to the FDA for breakthrough therapies Japan also has a variety of new drug review policies similar to those in Europe and the United States the U.S., Europe and Japan new drugs all kinds of accelerated review policies more competitive than the European and American Market SGLT-2 inhibitor market
only in Japan listed in the highest proportion of innovative drug indications is type 2 diabetes-based endocrine metabolic disease Diabetes is a highly satisfying disease in Japan, with high incidence and high drug costs, and is the driving force for the marketing of new diabetes drugs There are currently 6 SGLT-2 inhibitors and 3 compounds on the Japanese market the field of new drug treatments, which have been only marketed in Japan in the past 10 years
the effectiveness and safety of various SGLT-2 inhibitors are not very different, with the first-ever Ipoliflozin with its first-mover advantage and the introduction of the heavy-duty bomb drug Sitaliptin with MSD in 2018, sales continued to rise On March 24, 2014, three SGLT-2 inhibitors were approved, with Canagliflozin in cooperation with Tae-bian Mitsubishi and Japan-only Luseogliflozin and Tofogliflozin, who were relatively less experienced in sales than Johnson and Johnson and Takata sales of major SGLT-2 inhibitors in the Japanese market (in j.d.) Note: 2019 data focus on solving viral resistance and neglected infectious diseases based on previous sales forecasts Japan's research and development of new drugs against infectious diseases, focusing on the development of new drugs to address existing viral resistance and neglected tropical diseases, and making slow progress in the field of new antimicrobial preparations Lascufloxacin based on traditional quinolones to modify, while ensuring clinical efficacy while reducing side effects, including staphylococcus, streptococcus, catamora, influenza haemophilus, Crepobacteria, E coli, pneumococcal, other mycoplasma, such as pneumonia mycoplasma Lascufloxacin has a good inhibitory effect on these pathogenic microorganisms, but the WHO's other critical pathogenic microorganisms are ineffective Lascufloxacin is a quinolone antibiotic, is also currently applying to the FDA Fosravuconazole, an antifungal drug that is an oral phenyl triazole, approved for metformin in 2018, is the only new oral therapy approved for metformin in the last 20 years, and is the only new drug for the development of fungal foot swelling, an important neglected tropical disease, many patients with moderate to severe diseases are at risk of amputation or even death, and the efficacy of the drugs concocsinand and isocoquine is currently available for limited and severe adverse reactions Fosravuconazole is undergoing weekly treatment with the efficacy of isoconazole daily treatment Favipiravir polymerase inhibitors, whose mechanism sits primarily to interfere with the synthesis of the virus, are in the upper reaches of oseltamivir, which inhibits the release of the virus, are approved for use in patients with influenza A with oseltamivir, and are also known for their role as anti-Ebola virus and treated in the Congo as Ebola haemorrhagic fever in 2010 Japan approved two anti-flu drugs, both neuraminidase inhibitors, one is the injection agent Peramivir, the other is currently only listed in Japan dry powder inhaler Laninamivir, can be used for oseltamivir-resistant influenza, the former is faster fever rate, the latter is a long-acting inhibitor, can only be a single dose of treatment, is now also in China's clinical urgent need of new drugs (second batch) References: 1, FDA, PMDA 2, Pharmadigger Database